Photo from wikipedia
Key Points • JAK2, ABL, and MAPK signaling drive adaptive resistance to FLT3 inhibitors.• Polypharmacological targeting of FLT3, JAK2, ABL, and MAPK signaling provides a durable response in AML. Click to show full abstract
Key Points • JAK2, ABL, and MAPK signaling drive adaptive resistance to FLT3 inhibitors.• Polypharmacological targeting of FLT3, JAK2, ABL, and MAPK signaling provides a durable response in AML.
Keywords:
flt3 inhibitors;
adaptive resistance;
jak2 abl;
targeting flt3;
polypharmacological targeting;
resistance flt3
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!